The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors

Surgery

Volumn 144, Issue 4, 2008, Pages 645-653

  Chambers, Anthony J ^a,b,c   Pasieka, Janice L ^a,b   Dixon, Elijah ^a,b   Rorstad, Otto ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Divisions of Surgical Oncology and General Surgery   (Canada)

^c Division of Endocrinology ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; HUMAN; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MESENTERY TUMOR; MORBIDITY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MALIGNANT CARCINOID SYNDROME; MESENTERY; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PALLIATIVE CARE; PERITONEAL NEOPLASMS; PROBABILITY; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 51449107959     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.06.008     Document Type: Article

References (25)

1. Hemminki K., and Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92 (2001) 2204-2210
2. Maggard M.A., O'Connell J.B., and Ko C.Y. Updated population-based review of carcinoid tumors. Ann Surg 240 (2004) 117-122
3. Solcia E., Kloppel G., and Sobin L.H. Histological typing of endocrine tumours. 2nd edition (2000), Springer Verlag, Berlin, Germany
4. Moertel C.G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5 (1987) 1502-1522
5. Hellman P., Lundstrom T., Ohrvall U., Eriksson B., Skogseid B., Oberg K., et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26 (2002) 991-997
6. Makridis C., Rastad J., Oberg K., and Akerstrom G. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 20 (1996) 900-907
7. Soreide O., Berstad T., Bakka A., Schrumpf E., Hanssen L.E., Engh V., et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 111 (1992) 48-54
8. Oberg K., and Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol 30 (1991) 519-522
9. Pasieka J.L., McEwan A.J., and Rorstad O. The palliative role of 131I-MIBG and 111In-Octeotride therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 136 (2004) 1218-1226
10. Kvols L.K., Moertel C.G., O'Connell M.J., Schutt A.J., Rubin J., and Hahn R.G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315 (1986) 663-666
11. Boudreaux J.P., Putty B., Frey D.J., Woltering E., Anthony L., Daly I., et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 241 (2005) 839-845
12. Makridis C., Ekbom A., Bring J., Rastad J., Juhlin C., Oberg K., et al. Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 122 (1997) 1075-1082
13. Givi B., Pommier S.J., Thompson A.K., Diggs B.S., and Pommier R.F. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 140 (2006) 891-897
14. Ohrvall U., Eriksson B., Juhlin C., Karacagil S., Rastad J., Hellman P., et al. Method of dissection of mesenteric metastases in mid-gut carcinoid tumours. World J Surg 24 (2000) 1402-1408
15. Que F.G., Nagorney D.M., Batts K.P., Linz L.J., and Kvols L.K. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169 (1995) 36-42
16. Eriksson J., Stalberg P., Nilsson A., Krause J., Lundberg C., Skogseid B., et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg (2008) 32
17. Chung M.H., Pisegna J., Spirt M., Giuliano A.E., Ye W., Ramming K.P., et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130 (2001) 954-962
18. McEntee G.P., Nagorney D.M., Kvols L.K., Moertel C.G., and Grant C.S. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 (1990) 1091-1096
19. Musunuru S., Chen H., Rajpal S., Stephani N., McDermott J.C., Holen K., et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 141 (2006) 1000-1001
20. Sarmiento J.M., Heywood G., Rubin J., Ilstrup D.M., Nagorney D.M., and Que F.G. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 (2003) 29-37
21. Touzios J.G., Kiely J.M., Pitt S.C., Rilling W.S., Quebbeman E.J., Wilson S.D., et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg 241 (2005) 776-783
22. Chamberlain R.S., Canes D., Brown K.T., Saltz L., Jarnagin W., Fong Y., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-445
23. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 (2003) 934-959
24. Janson E.T., Holmberg L., Stridsberg M., Eriksson B., Theodorsson E., Wilander E., et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8 (1997) 685-690
25. Soreide J.A., Heerden J.A.V., Thompson G.B., Schleck C., Ilstrup D.M., and Churchward M. Gastrointestinal carcinoid tumours: long-term prognosis for surgically treated patients. World J Surg 24 (2000) 1431-1436